Ozempic Launches in India: Diabetes Drug Amidst Price Surge

Novo Nordisk has introduced Ozempic, a once-weekly injectable semaglutide treatment for Type 2 diabetes, into the Indian market. The initial dose of 0.25 mg is priced at Rs 2,200 per week, with monthly costs escalating for higher dosages. This medication aids in controlling blood sugar by stimulating insulin production and reducing liver glucose release, while also impacting appetite for weight management.

Experts highlight that Ozempic offers considerable benefits, including improved HbA1c levels, weight loss, and protection against cardiovascular and kidney complications associated with diabetes. However, a strong emphasis has been placed on the necessity of medical supervision during its administration, particularly for Indian patients exhibiting the 'thin-fat' phenotype, to ensure safe and effective treatment.